A plausible approach to circumvent roadblocks in generating tumor-specific CD8+ T cell responses against tumor antigens is through the use of cancer vaccines, where tumor antigen is delivered to the host to enhance antigen-specific immunity (4). This evidence concerns the gene CD8A and cancer.